Cargando…
Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study
BACKGROUND: Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role in the development of vascular events. Measurement of the peripheral vasodilat...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945366/ https://www.ncbi.nlm.nih.gov/pubmed/36814340 http://dx.doi.org/10.1186/s40959-023-00164-3 |
_version_ | 1784892127689310208 |
---|---|
author | Kaneko, Tomohiro Miyazaki, Sakiko Kurita, Azusa Morimoto, Ryoko Tsuchiya, Shun Watanabe, Naoki Takaku, Tomoiku Komatsu, Norio Minamino, Tohru |
author_facet | Kaneko, Tomohiro Miyazaki, Sakiko Kurita, Azusa Morimoto, Ryoko Tsuchiya, Shun Watanabe, Naoki Takaku, Tomoiku Komatsu, Norio Minamino, Tohru |
author_sort | Kaneko, Tomohiro |
collection | PubMed |
description | BACKGROUND: Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role in the development of vascular events. Measurement of the peripheral vasodilator response by peripheral arterial tonometry (PAT) has reportedly been useful in the non-invasive assessment of endothelial dysfunction. To date, no studies have assessed endothelial function using PAT in patients with CML receiving TKIs. METHOD: We measured the reactive hyperemia index (RHI) using PAT in young patients with CML (men aged ≤ 55 years and women aged ≤ 65 years) receiving TKIs. RESULTS: Thirty patients with CML were examined (mean age, 43.5 ± 9.8 years; men, 57%). The median RHI was 1.81. Among these patients, 16.7% and 83.3% were taking imatinib and second- or third-generation TKIs, respectively. There were no differences in the baseline characteristics between the low RHI (< 1.67, n = 10), borderline RHI (≥ 1.67 and < 2.10, n = 14), and normal RHI (≥ 2.10, n = 6) groups. Serum uric acid (UA) levels and the RHI were significantly negatively correlated (r = -0.40, p = 0.029). CONCLUSION: One-third of young patients with CML receiving TKI therapy were classified as having a low RHI. The RHI was negatively correlated with serum UA level. Larger prospective studies are necessary to examine whether the RHI predicts cardiovascular events in such patients. |
format | Online Article Text |
id | pubmed-9945366 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99453662023-02-23 Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study Kaneko, Tomohiro Miyazaki, Sakiko Kurita, Azusa Morimoto, Ryoko Tsuchiya, Shun Watanabe, Naoki Takaku, Tomoiku Komatsu, Norio Minamino, Tohru Cardiooncology Research BACKGROUND: Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role in the development of vascular events. Measurement of the peripheral vasodilator response by peripheral arterial tonometry (PAT) has reportedly been useful in the non-invasive assessment of endothelial dysfunction. To date, no studies have assessed endothelial function using PAT in patients with CML receiving TKIs. METHOD: We measured the reactive hyperemia index (RHI) using PAT in young patients with CML (men aged ≤ 55 years and women aged ≤ 65 years) receiving TKIs. RESULTS: Thirty patients with CML were examined (mean age, 43.5 ± 9.8 years; men, 57%). The median RHI was 1.81. Among these patients, 16.7% and 83.3% were taking imatinib and second- or third-generation TKIs, respectively. There were no differences in the baseline characteristics between the low RHI (< 1.67, n = 10), borderline RHI (≥ 1.67 and < 2.10, n = 14), and normal RHI (≥ 2.10, n = 6) groups. Serum uric acid (UA) levels and the RHI were significantly negatively correlated (r = -0.40, p = 0.029). CONCLUSION: One-third of young patients with CML receiving TKI therapy were classified as having a low RHI. The RHI was negatively correlated with serum UA level. Larger prospective studies are necessary to examine whether the RHI predicts cardiovascular events in such patients. BioMed Central 2023-02-22 /pmc/articles/PMC9945366/ /pubmed/36814340 http://dx.doi.org/10.1186/s40959-023-00164-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kaneko, Tomohiro Miyazaki, Sakiko Kurita, Azusa Morimoto, Ryoko Tsuchiya, Shun Watanabe, Naoki Takaku, Tomoiku Komatsu, Norio Minamino, Tohru Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
title | Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
title_full | Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
title_fullStr | Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
title_full_unstemmed | Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
title_short | Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
title_sort | endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945366/ https://www.ncbi.nlm.nih.gov/pubmed/36814340 http://dx.doi.org/10.1186/s40959-023-00164-3 |
work_keys_str_mv | AT kanekotomohiro endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT miyazakisakiko endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT kuritaazusa endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT morimotoryoko endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT tsuchiyashun endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT watanabenaoki endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT takakutomoiku endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT komatsunorio endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy AT minaminotohru endothelialfunctionmeasuredbyperipheralarterialtonometryinpatientswithchronicmyeloidleukemiaontyrosinekinaseinhibitortherapyapilotstudy |